Novavax stock: buy or sell
Jul 29th, 2021
Novavax stock brief
- Novavax stock exploded 5.59% to close at $189.01 on the stock market on Wednesday, and broke a streak of 4 sessions in red.
- The stock is configuring an uptrend pattern since last May, when it bottomed at $117.12. Up to date, shares made a 61.38% profit since the beginning of this rally
- Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs.
Should I buy Novavax stock?
Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best
Is $NVAX stock a buy?
In the current situation of Novavax there is just one buy setup eligible:
Uptrend buy setup
Novavax stock is in an uptrend since last May that so far has marked a gorgeous 61.00% gain. Price marked a local bottom in this uptrend at $172.01 on Tuesday, and since then it bounced up a 9.88%. Breaking out above $230.90 - it's last top - will be a good entry point if Novavax resumes the uptrend. If you decide to enter this trade, the suggested stop loss is at $207.81
|Buy setup||Buy point||Stop loss||Risk|
|Uptrend buy setup||$230.90||$207.81||10.00%|
Should I sell Novavax stock?
Knowing when to sell a stock is even harder than knowing when to buy it. Trading strategies prevent us from making rash decisions based on our personal feelings or the buzz that surrounds the market. When selling, as well as buying, our strategies are very easy to follow but are only applicable for selling shares you already own, not for selling short Novavax stock
As a rule of thumb, you should never hold an investment that produces higher than expected losses by the time of purchase. The moment to sell shares must always be determined by the stop-loss (automatic or manual)
Is it time to sell Novavax stock?
In the current situation of Novavax there is not any eligible sell setup, so Novavax stock holders with operations in green can keep their positions
In the last 30 days we couldn't find any rating for Novavax
Novavax stock analysis
Novavax stock started an uptrend last May, and gained a gorgeous 61.38%. During this uptrend, the price offered some buy points on the breakouts. Latest pullback was on Tuesday, when price bounced at $172.01. Like in all uptrends, price needs to rest and now price is moving in a range between $230.90 and $172.01
Supports and resistances
The current resistance levels are:
The current support levels are:
Relative strength index
When the moves for so long below 70 and above 30, without showing moments of overbought and oversold, the indicator turns out to be of little use, and we find ourselves in one of these situations.
Novavax stock price history
Novavax went public priced at an adjusted price1 of $67.50 on Dec 1995. Since then, NVAX stock has risen by 180.01%, with an average of 7.20% per year. An investment of $1,000USD at that time would worth $2,800.15 today.
1: Adjusted price after possible price splits or reverse-splits
Price target for Novavax stock
Nobody can predict how much a stock will be priced in the future. However, many stock price forecasts are published every day by banks, financial institutions and independent analysts.
Along with buy or sell recommendations, financial institutions post their price predictions based on the stock price action and the company fundamental data. Most of these predictions follow the release of new financial information by the company, and many times. Again, these targets are not direct recommendations for small investors and should not be trusted blindly.
In the last 30 days we couldn't find any price target published for Novavax stock.
Earnings and financials
Shareholders call was hosted by Novavax ($NVAX) last May after releasing the financial report. Novavax presented earnings of $-3.05 per share on revenue of $447.2 million. The market estimate was $-3.60 per share on revenue of $233.9 million.Same quarter one year ago, reported EPS was $-0.58, so recently posted EPS means a loss of -425.86%. Looking at turnover, figures exploded a 13,143.38% compared to $33.8M same quarter a year ago.
Novavax ($NVAX) presents earnings report next Monday. Analysts predict of $-3.63, that is a 19.02% lower than Q1.
Disclaimer:The opinions given in this post are personal and should not be followed as recommendations for you to buy or sell stocks. The author of this report does not have an understanding of the particular scenarios of the reader, his or her financial statements or what is in his or her best interest at any given time. All users should speak with their financial advisor before buying or selling any securities Comments are published for informational purposes only
|Wednesday, July 28th, 2021|
|Day range||$180.37 - $189.48|
|Average true range||$18.04|
|50d mov avg||$184.55|
|100d mov avg||$188.20|
|200d mov avg||$167.26|
|Earnings date||August 9th, 2021|
Frequently asked questions
What is Novavax stock symbol?
Is Novavax stock a buy or sell?
Will NVAX go up?
Latest Novavax news
- InvestorPlaceVaccines Aren’t Winner-Take-All, Making Novavax Stock a Smart Covid PlayNov 19, 2020
- InvestorPlaceThe Red Ink on Novavax Only Hides Its True PotentialNov 19, 2020